Weeing more at night, a weak flow or blood in your urine are worth a GP visit. Black men can ask about the PSA test from 45, an Oxford cancer specialist says.

Early prostate cancer often causes no symptoms at all, so the men most at risk should not wait for one before talking to a GP. When signs do appear, the ones to get checked are needing to wee more often, especially at night, trouble starting or keeping up the flow, blood in the urine, erectile problems, lower back pain and losing weight without trying.

That is the advice of Dr David Gauden, chief executive of Blue Earth Therapeutics, a cancer drug company at Oxford Science Park, who answered our questions in writing for Movember.

Overview

  • Symptoms to get checked: weeing more often (especially at night), a hard-to-start or weak flow, blood in the urine, erectile dysfunction, lower back pain, weight loss you cannot explain
  • No symptoms? Men at higher risk should still speak to a GP
  • Higher risk: men over 50, Black men, and men whose father or brother had prostate cancer
  • Black men: Prostate Cancer UK recommends talking to a GP about risk and the PSA test from age 45
  • The PSA test: useful but not perfect; a GP weighs it with your age and risk

The symptoms not to ignore

“One of the challenges with prostate cancer is that it often causes no symptoms in its early stages,” Dr Gauden said. “However, as prostate cancer develops, some people may experience changes that should be discussed with a GP.

“These can include changes in urinary habits, such as needing to urinate more often, especially at night, or difficulty starting or maintaining the flow of urine. Other symptoms can include blood in the urine, erectile dysfunction, lower back pain, or losing weight without trying to.”

None of these means cancer on its own. “These symptoms can have causes other than cancer, but it is sensible to have them checked,” he said. “Anyone who is concerned about prostate cancer, including people without symptoms who may be at higher risk, should speak to their GP about their individual circumstances.”

About two dozen Blue Earth Therapeutics staff standing in a row outside a glass-fronted building, with trees behind
The Blue Earth Therapeutics team outside their building. Photo: Matthew Ellacott Photography, supplied by Blue Earth Therapeutics

Who is most at risk, and when to ask a GP

Age, family history and ethnicity all raise the risk, Dr Gauden said, and “some inherited genetic factors can also affect an individual’s risk.”

“The chance of developing prostate cancer increases after the age of 50, with more cases diagnosed after age 65,” he said. “Black men have a higher risk of developing prostate cancer than the wider male population in the UK, and Prostate Cancer UK recommends that Black men speak to their GP about their risk and the PSA blood test from the age of 45. A family history of prostate cancer, particularly in a father or brother, can also increase risk.”

His advice is to know where you stand: “It is important for people to understand their own risk and discuss it with a GP, who can advise on whether testing may be appropriate.”

Should you ask for a PSA test?

The UK has no national screening programme for prostate cancer. The PSA blood test is the starting point, but Dr Gauden is clear about its limits.

“The PSA blood test can be a useful part of assessing prostate cancer risk, but it is not a perfect test,” he said. “A raised PSA does not necessarily mean that someone has prostate cancer, and prostate cancer can sometimes be present without a markedly raised PSA. Testing is therefore considered alongside an individual’s age, risk factors and other clinical information.”

There is better news on what happens next. “Fortunately, follow up diagnostic tests after a PSA are getting increasingly sophisticated,” he said. “The balance of benefits and limitations of PSA testing and screening continues to be an important area of research and public health discussion. People who are concerned about their risk should speak to their GP so they can make an informed decision based on their own circumstances and current NHS guidance.”

The NHS sets out its own advice on prostate cancer symptoms, and Prostate Cancer UK has more on risk and testing.

What has changed in the past five years

“One of the biggest changes is the growing recognition that prostate cancer is not one single disease and that it can behave very differently in different people,” Dr Gauden said.

“Research is increasingly focused on understanding the biology of an individual cancer and using that information to help identify which approaches may be most appropriate at different stages of disease. There has also been significant progress in imaging, diagnostics, and targeted treatments. Together, these advances are helping researchers explore a more personalised approach to care, while clinical trials remain essential to establish which new approaches are safe and effective and which patients may benefit.”

A large group of Blue Earth Therapeutics staff in evening dress on a terrace in front of a stone building with a rose window
Blue Earth Therapeutics staff on a terrace. Photo: Potters Instinct Photography, supplied by Blue Earth Therapeutics

What the Oxford Science Park company is testing

Blue Earth Therapeutics is a clinical-stage biotechnology company working on radiopharmaceuticals, with its current clinical work focused on advanced prostate cancer.

“Radiopharmaceutical therapies are medicines designed to carry radiation to a biological target associated with cancer cells, with the aim of treating the cancer while limiting exposure to healthy tissues as far as possible,” Dr Gauden said.

“Our prostate cancer research includes programmes that have progressed into Phase 1 and Phase 2 clinical trials. Phase 1 trials test a new treatment in a small group of patients to assess its safety, understand side effects, and find a suitable dose. Phase 2 trials then look at how well the treatment works, usually in a larger group of patients, while continuing to monitor safety.”

The company plans to start Phase 3 trials next year. “These remain investigational therapies, and further clinical trials are needed to establish their safety and effectiveness,” he said. “When any investigational therapy might become available to patients outside a clinical trial depends on the results of the ongoing research and subsequent regulatory review.”

Why Oxford, and what personalised care means for a patient

“Oxford provides a strong environment for a biotechnology company, with a well-established life-sciences community and access to scientific, clinical and research expertise,” Dr Gauden said. The company is “relatively small, very specialist”, with around 25 employees across the UK and US.

On personalised care, he said treatment decisions “are not simply about the type of cancer”, and that “biological profiling and targeting of the cancer is increasingly critical.”

“Clinicians may also consider the stage of the disease, previous treatment, general health, relevant test results, and the individual patient’s circumstances and priorities. The aim is to use the available evidence to help select the most appropriate care for that individual, and these decisions are made by patients together with their treating healthcare professionals.”

Five members of the Blue Earth Therapeutics executive team standing on a wooden terrace with planters and trees behind
The Blue Earth Therapeutics executive team. Photo: Potters Instinct Photography, supplied by Blue Earth Therapeutics

With thanks to Dr David Gauden and Blue Earth Therapeutics for answering our questions.